Q-State Biosciences and 2bPrecise Announce Partnership
August 13 2019 - 8:01AM
Business Wire
Initiative designed to accelerate discovery of
genetically targeted medicines and broaden options for enhanced
patient care
Q-State Biosciences and 2bPrecise will partner to build robust
clinical-genomic datasets enabling healthcare providers to better
leverage precision medicine when treating patients with genetic
conditions. The collaboration will facilitate the advance of novel
insights that health systems can incorporate to improve clinical
practice and that pharmaceutical companies can use in the
development of new therapies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190813005395/en/
The partnership – backed by 2bPrecise parent company Allscripts
Healthcare Solutions (Nasdaq:MDRX) – will combine 2bPrecise’s
cloud-based, EHR-independent platform that brings genomic data into
the clinical workflow with Q-State’s whole-genome and whole-exome
sequencing, transcriptomics and leading functional phenotyping
capabilities. The collaboration will benefit patients and care
organizations by supporting improved diagnostic yields and patient
outcomes, and by providing clinical tools to help match patients
with precise therapies based on their health attributes and genetic
profile. Likewise, it will help pharmaceutical firms accelerate
therapeutic discovery through the identification of novel disease
targets, stratification of patient populations and expedited
clinical-trial recruitment paths.
“Genomic data holds the power to evolve the entire healthcare
industry. Today, patients’ genetic information enables not only
diagnoses, but also systematic identification of disease targets
and synthesis of new genetically targeted medicines,” said Q-State
CEO Matthew Fox.
“This partnership facilitates healthcare innovation that enables
precision medicine and genetically-based clinical care on a
transformative scale,” said 2bPrecise Founder and CEO Assaf Halevy.
“We are excited to collaborate with our Q-State colleagues on novel
ways to accelerate access to new therapies.”
About Q-State Biosciences Q-State Biosciences is a
precision medicine company based in Cambridge, MA, that pioneers
revolutionizing care for patients with devastating genetic
disorders. Q-State applies a proprietary platform to diagnose the
root cause of disease and to discover genetically targeted
therapies. For more information, please visit
www.qstatebio.com.
About 2bPrecise The cloud-based 2bPrecise platform
consumes genomic/genetic data from molecular labs and clinical
information from the client’s preferred EHR, combining them into a
comprehensive patient record. The solution provides insights from
multiple curated, evidence-based knowledgebases and injects the
data back into the provider’s native workflow. The 2bPrecise
platform creates a discrete information layer that follows the
patient as he or she moves into various clinical settings, so the
entire care team can access valuable insights – preventing
information from being isolated in a single care encounter or
specialty area, while enabling providers to arrive at accurate
diagnoses sooner and deliver therapeutic value faster. Learn more
at www.2bPreciseHealth.com.
About Allscripts Allscripts (NASDAQ: MDRX) is a leader in
healthcare information technology solutions that advance clinical,
financial and operational results. Our innovative solutions connect
people, places and data across an Open, Connected Community of
Health™. Connectivity empowers caregivers to make better decisions
and deliver better care for healthier populations. To learn more,
visit www.allscripts.com, Twitter, YouTube and
It Takes A Community: The Allscripts Blog.
© 2019 Allscripts Healthcare, LLC and/or its affiliates. All
Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are
trademarks of Allscripts Healthcare, LLC and/or its affiliates. All
other products are trademarks of their respective holders, all
rights reserved. Reference to these products is not intended to
imply affiliation with or sponsorship of Allscripts Healthcare, LLC
and/or its affiliates.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190813005395/en/
Investors: Stephen Shulstein
312-386-6735 Stephen.Shulstein@allscripts.com
Media: Aria Marketing Danielle
Johns 617-332-9999 x241 djohns@ariamarketing.com
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Sep 2023 to Sep 2024